Skip to main content
SpringerLink
Log in

Immune-Related Oral, Otologic, and Ocular Adverse Events

  • Chapter
  • First Online:
Immunotherapy

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1342))

Abstract

Emerging immunotherapeutic agents, including immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death protein ligand 1 (PD-L1), have revolutionized cancer treatment. The first immune checkpoint inhibitor (ICI) ipilimumab, an anti-CTLA-4, was approved in 2011. Since then, the US Food and Drug Administration (FDA) has approved more than half a dozen immune checkpoint inhibitors to treat various malignancies. These agents are part of a broader class of chemotherapy agents termed immunotherapy, which selectively target different steps in the immune response cascade to upregulate the body’s normal response to cancer. While the effects of traditional chemotherapy are well known, the toxicity profile of emerging immune therapies is not fully elucidated. They have been associated with atypical side effects labeled collectively as immune-related adverse events (irAEs).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Centerwatch Database of FDA Approved Drugs. Available from: http://www.centerwatch.com

  2. Fraunfelder, F. T., Fraunfelder, F. W., & Chambers, W. A. (2008). Clinical ocular toxicology e-book: Drug-induced ocular side effects. Elsevier Health Sciences.

    Google Scholar 

  3. Lalla, R. V., & Peterson, D. E. (2005). Oral mucositis. Dental Clinics of North America, 49(1), 167–184, ix.

    Article  PubMed  Google Scholar 

  4. Sonis, S. T., Elting, L. S., Keefe, D., Peterson, D. E., Schubert, M., Hauer-Jensen, M., et al. (2004). Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer, 100(9 Suppl), 1995–2025.

    Article  PubMed  Google Scholar 

  5. Treister, N., & Sonis, S. (2007). Mucositis: Biology and management. Current Opinion in Otolaryngology & Head and Neck Surgery, 15(2), 123–129.

    Article  Google Scholar 

  6. Lalla, R. V., Sonis, S. T., & Peterson, D. E. (2008). Management of oral mucositis in patients who have cancer. Dental Clinics of North America, 52(1), 61–77. viii.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Sonis, S. T. (2004). The pathobiology of mucositis. Nature Reviews Cancer, 4(4), 277–284.

    Article  CAS  PubMed  Google Scholar 

  8. Berger, K., Schopohl, D., Bollig, A., Strobach, D., Rieger, C., Rublee, D., et al. (2018). Burden of oral mucositis: A systematic review and implications for future research. Oncology Research and Treatment, 41(6), 399–405.

    Article  PubMed  Google Scholar 

  9. Pinna, R., Campus, G., Cumbo, E., Mura, I., & Milia, E. (2015). Xerostomia induced by radiotherapy: An overview of the physiopathology, clinical evidence, and management of the oral damage. Therapeutics and Clinical Risk Management, 11, 171–188.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Jensen, S. B., Pedersen, A. M., Vissink, A., Andersen, E., Brown, C. G., Davies, A. N., et al. (2010). A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: Prevalence, severity and impact on quality of life. Supportive Care in Cancer, 18(8), 1039–1060.

    Article  CAS  PubMed  Google Scholar 

  11. Jensen, S. B., Pedersen, A. M., Reibel, J., & Nauntofte, B. (2003). Xerostomia and hypofunction of the salivary glands in cancer therapy. Supportive Care in Cancer, 11(4), 207–225.

    Article  PubMed  Google Scholar 

  12. Nyaga, V. N., Arbyn, M., & Aerts, M. (2014). Metaprop: A Stata command to perform meta-analysis of binomial data. Archives of Public Health, 72(1), 39.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Sterne, J. A., & Egger, M. (2001). Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. Journal of Clinical Epidemiology, 54(10), 1046–1055.

    Article  CAS  PubMed  Google Scholar 

  14. Higgins, J. P., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ, 327(7414), 557–560.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Owosho, A. A., Scordo, M., Yom, S. K., Randazzo, J., Chapman, P. B., Huryn, J. M., et al. (2015). Osteonecrosis of the jaw a new complication related to Ipilimumab. Oral Oncology, 51(12), e100–e101.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Naidoo, J., Schindler, K., Querfeld, C., Busam, K., Cunningham, J., Page, D. B., et al. (2016). Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunology Research, 4(5), 383–389.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Jour, G., Glitza, I. C., Ellis, R. M., Torres-Cabala, C. A., Tetzlaff, M. T., Li, J. Y., et al. (2016). Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: A report on bullous skin eruptions. Journal of Cutaneous Pathology, 43(8), 688–696.

    Article  PubMed  Google Scholar 

  18. Zumelzu, C., Alexandre, M., Le Roux, C., Weber, P., Guyot, A., Levy, A., et al. (2018). Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1/ programmed death-ligand 1: A case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature. Front Med (Lausanne), 5, 268.

    Article  Google Scholar 

  19. Schaberg, K. B., Novoa, R. A., Wakelee, H. A., Kim, J., Cheung, C., Srinivas, S., et al. (2016). Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. Journal of Cutaneous Pathology, 43(4), 339–346.

    Article  PubMed  Google Scholar 

  20. Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., et al. (2009). Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood, 114(3), 535–546.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Seaman, B. J., Guardiani, E. A., Brewer, C. C., Zalewski, C. K., King, K. A., Rudy, S., et al. (2012). Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma. Otolaryngology and Head and Neck Surgery, 147(4), 744–749.

    Article  Google Scholar 

  22. Steel, K. P., & Barkway, C. (1989). Another role for melanocytes: Their importance for normal stria vascularis development in the mammalian inner ear. Development, 107(3), 453–463.

    Article  CAS  PubMed  Google Scholar 

  23. Kim, H. J., Gratton, M. A., Lee, J. H., Perez Flores, M. C., Wang, W., Doyle, K. J., et al. (2013). Precise toxigenic ablation of intermediate cells abolishes the “battery” of the cochlear duct. The Journal of Neuroscience, 33(36), 14601–14606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Wingard, J. C., & Zhao, H. B. (2015). Cellular and deafness mechanisms underlying connexin mutation-induced hearing loss – A common hereditary deafness. Frontiers in Cellular Neuroscience, 9, 202.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Izumi, K., Kohta, T., Kimura, Y., Ishida, S., Takahashi, T., Ishiko, A., et al. (2008). Tietz syndrome: unique phenotype specific to mutations of MITF nuclear localization signal. Clinical Genetics, 74(1), 93–95.

    Article  CAS  PubMed  Google Scholar 

  26. Asher, J. H., Jr., Sommer, A., Morell, R., & Friedman, T. B. (1996). Missense mutation in the paired domain of PAX3 causes craniofacial-deafness-hand syndrome. Human Mutation, 7(1), 30–35.

    Article  CAS  PubMed  Google Scholar 

  27. Drozniewska, M., & Haus, O. (2014). PAX3 gene deletion detected by microarray analysis in a girl with hearing loss. Molecular Cytogenetics, 7, 30.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Pingault, V., Ente, D., Dastot-Le Moal, F., Goossens, M., Marlin, S., & Bondurand, N. (2010). Review and update of mutations causing Waardenburg syndrome. Human Mutation, 31(4), 391–406.

    Article  CAS  PubMed  Google Scholar 

  29. Chaoui, A., Watanabe, Y., Touraine, R., Baral, V., Goossens, M., Pingault, V., et al. (2011). Identification and functional analysis of SOX10 missense mutations in different subtypes of Waardenburg syndrome. Human Mutation, 32(12), 1436–1449.

    Article  CAS  PubMed  Google Scholar 

  30. Greco, A., Fusconi, M., Gallo, A., Turchetta, R., Marinelli, C., Macri, G. F., et al. (2013). Vogt-Koyanagi-Harada syndrome. Autoimmunity Reviews, 12(11), 1033–1038.

    Article  CAS  PubMed  Google Scholar 

  31. Spielbauer, K., Cunningham, L., & Schmitt, N. (2018). PD-1 inhibition minimally affects cisplatin-induced toxicities in a murine model. Otolaryngology and Head and Neck Surgery, 159(2), 343–346.

    Article  Google Scholar 

  32. Szepesy, J., Miklós, G., Farkas, J., Kucsera, D., Giricz, Z., Gáborján, A., et al. (2020). Anti-PD-1 therapy does not influence hearing ability in the most sensitive frequency range, but mitigates outer hair cell loss in the basal cochlear region. International Journal of Molecular Sciences, 21(18), 6701.

    Article  CAS  PubMed Central  Google Scholar 

  33. Kuzucu, İ., Baklacı, D., Guler, İ., Uçaryılmaz, E. Ö., Kum, R. O., & Özcan, M. (2019). Investigation of the ototoxic effect of pembrolizumab using a rat model. Cureus, 11(11), e6057. https://doi.org/10.7759/cureus.6057. PMID: 31827988; PMCID: PMC6890160.

  34. Rosner, S., Agrawal, Y., Sun, D. Q., Aygun, N., Schollenberger, M. D., Lipson, E., et al. (2020). Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. Journal for Immunotherapy of Cancer, 8(2), e001675. https://doi.org/10.1136/jitc-2020-001675. PMID: 33335030; PMCID: PMC7745691.

  35. Zibelman, M., Pollak, N., & Olszanski, A. J. (2016). Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. Journal for Immunotherapy of Cancer, 4, 8.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Diamantopoulos, P. T., Stoungioti, S., Anastasopoulou, A., Papaxoinis, G., & Gogas, H. (2018). Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma. Melanoma Research, 28(6), 648–651.

    Article  PubMed  Google Scholar 

  37. Tampio, A. D. S., Sivapiragasam, A., & Nicholas, B. (2019). Bilateral sensorineural hearing loss and panuveitis in a man with stage IV malignant melanoma after nivolumab immunotherapy. Poster Presentation presented at the: Combined Otolaryngology Spring Meetings 2019; May 3, 2019; Austin, TX. https://wwwresearchposterscom/display_postersaspx?code=cosm2019

    Google Scholar 

  38. Hobelmann, K., & Fitzgerald, D. (2019). A case of pembrolizumab induced autoimmune sensorineural hearing loss. Journal of Otology & Rhinology, 8, 1.

    Google Scholar 

  39. Rajapakse, A., O’Leary, C., Gundelach, R., Deva, R., & O’Byrne, K. (2020). Unilateral autoimmune inner ear disease in a patient with lung cancer treated with nivolumab. Oxford Medical Case Reports, 2020(9), omaa077.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Choi, J. S., Chen, M., McQuade, J. L., Appelbaum, E., Gidley, P. W., & Nader, M. E. (2020). Recurrent audiovestibular dysfunction and associated neurological immune-related adverse events in a melanoma patient treated with nivolumab and ipilimumab. Head & Neck, 42(11), E35–E42.

    Article  Google Scholar 

  41. Gambichler, T., Seifert, C., Lehmann, M., Lukas, C., Scheel, C., & Susok, L. (2020). Concurrent Vogt–Koyanagi–Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma. Immunotherapy, 12(7), 439–444.

    Article  CAS  PubMed  Google Scholar 

  42. Ando, T., Ueda, A., Ogawa, K., Motoo, I., Kajiura, S., Nakajima, T., et al. (2021). Prognosis of immune-related adverse events in patients with advanced gastric cancer treated with nivolumab or pembrolizumab: A multicenter retrospective analysis. In Vivo, 35(1), 475–482.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Masuda, K., Shoji, H., Nagashima, K., Yamamoto, S., Ishikawa, M., Imazeki, H., et al. (2019). Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer, 19(1), 974.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Fujii, T., Colen, R. R., Bilen, M. A., Hess, K. R., Hajjar, J., Suarez-Almazor, M. E., et al. (2018). Incidence of immune-related adverse events and its association with treatment outcomes: The MD Anderson Cancer Center experience. Investigational New Drugs, 36(4), 638–646.

    Article  CAS  PubMed  Google Scholar 

  45. Centerwatch Database of FDA Approved Drugs. Available from: http://www.centerwatch.com

  46. Basti, S. (2007). Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nursing, 30(4 Suppl 1), S10–S16.

    Article  PubMed  Google Scholar 

  47. Dalvin, L. A., Shields, C. L., Orloff, M., Sato, T., & Shields, J. A. (2018). CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic indications and ophthalmic side effects. Retina (Philadelphia, Pa), 38(6), 1063–1078.

    Article  CAS  Google Scholar 

  48. Fu, C., Gombos, D. S., Lee, J., George, G. C., Hess, K., Whyte, A., et al. (2017). Ocular toxicities associated with targeted anticancer agents: An analysis of clinical data with management suggestions. Oncotarget, 8(35), 58709–58727.

    Article  PubMed  PubMed Central  Google Scholar 

  49. National Cancer Institute (U.S.). (2009). Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE).

    Google Scholar 

  50. Blanke, C. D., Rankin, C., Demetri, G. D., Ryan, C. W., von Mehren, M., Benjamin, R. S., et al. (2008). Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26(4), 626–632.

    Article  CAS  Google Scholar 

  51. Draganova, D., Kerger, J., Caspers, L., & Willermain, F. (2015). Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib. Journal of Ophthalmic Inflammation and Infection, 5, 17.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Lacouture, M. E. (2006). Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews Cancer, 6(10), 803–812.

    Article  CAS  PubMed  Google Scholar 

  53. Perez-Soler, R., Chachoua, A., Hammond, L. A., Rowinsky, E. K., Huberman, M., Karp, D., et al. (2004). Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 22(16), 3238–3247.

    Article  CAS  Google Scholar 

  54. Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine, 353(2), 123–132.

    Article  CAS  PubMed  Google Scholar 

  55. Abdel-Rahman, O., Oweira, H., Petrausch, U., Helbling, D., Schmidt, J., Mannhart, M., et al. (2017). Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: A systematic review. Expert Review of Anticancer Therapy, 17(4), 387–394.

    Article  CAS  PubMed  Google Scholar 

  56. Robert, C. S. J., Long, G. V., et al. (2015). Pembrolizumab versus ipilimumab in advanced melanoma. The New England Journal of Medicine, 372(26), 2521–2532.

    Article  CAS  PubMed  Google Scholar 

  57. Eltobgy, M., Oweira, H., Petrausch, U., Helbling, D., Schmidt, J., Mehrabi, A., et al. (2017). Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: A systematic review. Expert Review of Neurotherapeutics, 17(7), 725–736.

    Article  CAS  PubMed  Google Scholar 

  58. Antoun, J., Titah, C., & Cochereau, I. (2016). Ocular and orbital side-effects of checkpoint inhibitors: A review article. Current Opinion in Oncology, 28(4), 288–294.

    Article  CAS  PubMed  Google Scholar 

  59. Papavasileiou, E., Prasad, S., Freitag, S. K., Sobrin, L., & Lobo, A. M. (2016). Ipilimumab-induced ocular and orbital inflammation—A case series and review of the literature. Ocular Immunology and Inflammation, 24(2), 140–146.

    CAS  PubMed  Google Scholar 

  60. Bitton, K., Michot J. M., Barreau E., et al. (2019). Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PDL1 anticancer immunotherapy. American Journal of Ophthalmology, 202, 109–117. https://doi.org/10.1016/j.ajo.2019.02.012. Epub 2019 Feb 15. PMID: 30772350.

  61. Fang, T., Maberley, D. A., & Etminan, M. (2019). Ocular adverse events with immune checkpoint inhibitors. Journal of Current Ophthalmology, 31(3), 319–322.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Alba-Linero, C., & Alba, E. (2021). Ocular side effects of checkpoint inhibitors. Survey of Ophthalmology, 66(6), 951–959. https://doi.org/10.1016/j.survophthal.2021.01.001. Epub 2021 Jan 10. PMID: 33440195.

  63. Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., et al. (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor Therapy: American society of clinical oncology clinical practice guideline. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 36(17), 1714–1768.

    Article  CAS  Google Scholar 

  64. Horvat, T. Z., Adel, N. G., Dang TO, Momtaz, P., Postow, M. A., Callahan, M. K., et al. (2015). Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with Ipilimumab at Memorial Sloan Kettering cancer center. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 33(28), 3193–3198.

    Article  CAS  Google Scholar 

  65. Liu, Y., & Liu, Z. G. (2007). [Role of epidermal growth factor and its receptor family in ocular surface wound healing]. [Zhonghua yan ke za zhi] Chinese Journal of Ophthalmology, 43(10), 953–956.

    Google Scholar 

  66. Naing, A., Hajjar, J., Gulley, J. L., Atkins, M. B., Ciliberto, G., Meric-Bernstam, F., et al. (2020). Strategies for improving the management of immune-related adverse events. Journal for Immunotherapy of Cancer, 8(2), e001754. https://doi.org/10.1136/jitc-2020-001754. PMID: 33310772; PMCID: PMC7735083.

  67. Hajjar, J., Mendoza, T., Zhang, L., Fu, S., Piha-Paul, S. A., Hong, D. S., et al. (2021). Associations between the gut microbiome and fatigue in cancer patients. Scientific Reports, 11(1), 5847.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Fujii, T., Naing, A., Rolfo, C., & Hajjar, J. (2018). Biomarkers of response to immune checkpoint blockade in cancer treatment. Critical Reviews in Oncology/Hematology, 130, 108–120.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Head and Neck Surgery, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Nagham Al-Zubidi, J. Cody Page, Dan S. Gombos, Akanksha Srivastava, Eric Appelbaum, Paul W. Gidley, Mark S. Chambers & Marc-Elie Nader

Authors
  1. Nagham Al-Zubidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Cody Page
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dan S. Gombos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akanksha Srivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eric Appelbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paul W. Gidley
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mark S. Chambers
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marc-Elie Nader
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc-Elie Nader .

Editor information

Editors and Affiliations

  1. Professor, Dept. of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Aung Naing

  2. Assistant Professor, Service Chief of Adult Allergy & Immunology, Division of Immunology, Allergy & Retrovirology Baylor College of Medicine and Texas Children’ Hospital, Houston, TX, USA

    Joud Hajjar

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Al-Zubidi, N. et al. (2021). Immune-Related Oral, Otologic, and Ocular Adverse Events. In: Naing, A., Hajjar, J. (eds) Immunotherapy. Advances in Experimental Medicine and Biology, vol 1342. Springer, Cham. https://doi.org/10.1007/978-3-030-79308-1_17

Download citation

Publish with us

Policies and ethics

Search

Navigation